RARE - Why Is Mereo BioPharma Stock Trading Higher Today? | Benzinga
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) released interim data from the Phase 2 portion of the Phase 2/3 Orbit study of setrusumab.
The data demonstrated that treatment with setrusumab (UX143) significantly reduced the incidence of fractures in patients with osteogenesis imperfecta (OI) with at least six months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density (BMD).
The data were presented at the American Society for Bone and Mineral Research 2023 Annual Meeting.
The annualized fracture rate across all 24 patients in the ...